Worldcrunch on MSN16h
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?
That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...
Medscape3d
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
BioSpace8d
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
GlobalData on MSN10d
Eisai lowers Leqembi revenue forecast after rocky entry to market
Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.
manilatimes12d
BrightSpring Health Services Announces CareMed Was Selected as a National Specialty Pharmacy Partner for Leqembi®
BrightSpring Health Services ("BrightSpring” or "BrightSpring Health Services”) (NASDAQ: BTSG) is proud that CareMed, a ...
Morningstar11d
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 - March 2025). Sales now expected to reach JPY 42.5 billion
In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the ...
Life-changing Alzheimer's drug approved for use in EU to reduce cognitive decline
A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...
Medpage Today on MSN7d
Alzheimer's Data Withdrawn
A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...
Nottinghamshire Live on MSN3d
EU approves life changing 'important' Alzheimer's drug which can drastically slow onset
Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...